Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 18, 2022 - Issue 5
Submit an article Journal homepage
2,176
Views
7
CrossRef citations to date
0
Altmetric
Coronavirus – Research Paper

Individual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study

Masaki Machidaa Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, Japan;b Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-7060-7305View further author information
ORCID Icon,
Hiroyuki Kikuchia Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-0510-1030View further author information
ORCID Icon,
Takako Kojimac Department of International Medical Communications, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8300-2690View further author information
ORCID Icon,
Itaru Nakamurab Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0001-8494-1278View further author information
ORCID Icon,
Reiko Saitod Division of International Health (Public Health), Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JapanORCID Iconhttps://orcid.org/0000-0002-1554-8226View further author information
ORCID Icon,
Tomoki Nakayae Graduate School of Environmental Studies, Tohoku University, Sendai, JapanORCID Iconhttps://orcid.org/0000-0002-3827-1012View further author information
ORCID Icon,
Tomoya Hanibuchie Graduate School of Environmental Studies, Tohoku University, Sendai, JapanORCID Iconhttps://orcid.org/0000-0002-0447-7645View further author information
ORCID Icon,
Tomoko Takamiyaa Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-0821-9675View further author information
ORCID Icon,
Yuko Odagiria Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-7603-4800View further author information
ORCID Icon,
Noritoshi Fukushimaa Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0003-1819-554XView further author information
ORCID Icon,
Shiho Amagasaa Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-6047-0771View further author information
ORCID Icon,
Hidehiro Watanabeb Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, JapanORCID Iconhttps://orcid.org/0000-0002-1835-9543View further author information
ORCID Icon &
Shigeru Inouea Department of Preventive Medicine and Public Health, Tokyo Medical University, Tokyo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1931-2613View further author information
ORCID Icon show all
Article: 2086773 | Received 26 Feb 2022, Accepted 03 Jun 2022, Published online: 16 Jun 2022

References

  • World Health Organization. Coronavirus disease (COVID-19) pandemic. [accessed 2022 Feb 24]. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
  • Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, Brooks N, Smaja M, Mircus G, Pan K, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021;397(10287):1–7. doi:10.1016/S0140-6736(21)00947-8.
  • El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, et al. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021;385(19):1774–1785. doi:10.1056/NEJMoa2113017.
  • Falsey AR, Sobieszczyk ME, Hirsch I, Sproule S, Robb ML, Corey L, Neuzil KM, Hahn W, Hunt J, Mulligan MJ, et al. Phase 3 safety and efficacy of AZD1222 (ChAdox1 nCov-19) Covid-19 vaccine. N Engl J Med. 2021;385(25):2348–2360. doi:10.1056/NEJMoa2105290.
  • Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, Frankland TB, Ogun OA, Zamparo JM, Gray S, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet. 2021;398(10309):1407–1416. doi:10.1016/S0140-6736(21)02183-8.
  • de Figueiredo A, Simas C, Karafillakis E, Paterson P, Larson HJ. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: a large-scale retrospective temporal modelling study. Lancet. 2020;396(10255):898–908. doi:10.1016/S0140-6736(20)31558-0.
  • Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, Kimball S, El-Mohandes A. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–228. doi:10.1038/s41591-020-1124-9.
  • Sallam M. COVID-19 vaccine hesitancy worldwide: a concise systematic review of vaccine acceptance rates. Vaccines. 2021;9:160. doi:10.3390/vaccines9020160.
  • MacDonald NE, SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine. 2015;33(34):4161–4164. doi:10.1016/j.vaccine.2015.04.036.
  • O’-Callaghan KP, Blatz AM, Offit PA. Developing a SARS-CoV-2 vaccine at warp speed. JAMA. 2020;324(5):437–438. doi:10.1001/jama.2020.12190.
  • Calina D, Hartung T, Docea AO, Spandidos DA, Egorov AM, Shtilman MI, Carvalho F, Tsatsakis A. COVID-19 vaccines: Ethical framework concerning human challenge studies. Daru. 2020;28(2):807–812. doi:10.1007/s40199-020-00371-8.
  • Slaoui M, Hepburn M. Developing safe and effective Covid vaccines — operation warp speed’s strategy and approach. N Engl J Med. 2020;383(18):1701–1703. doi:10.1056/NEJMp2027405.
  • Robinson E, Jones A, Lesser I, Daly M. International estimates of intended uptake and refusal of COVID-19 vaccines: a rapid systematic review and meta-analysis of large nationally representative samples. Vaccine. 2021;39(15):2024–2034. doi:10.1016/j.vaccine.2021.02.005.
  • Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: how many people would get vaccinated? Vaccine. 2020;38(42):6500–6507. doi:10.1016/j.vaccine.2020.08.043.
  • Al-Mohaithef M, Padhi BK. Determinants of COVID-19 vaccine acceptance in Saudi Arabia: a web-based national survey. J Multidiscip Healthc. 2020;13:1657–1663. doi:10.2147/JMDH.S276771.
  • Zarocostas J. How to fight an infodemic. Lancet. 2020;395(10225):676. doi:10.1016/S0140-6736(20)30461-X.
  • van der Linden S, Roozenbeek J, Compton J. Inoculating against fake news about COVID-19. Front Psychol. 2020;11:566790. doi:10.3389/fpsyg.2020.566790.
  • Hannah Ritchie EM, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, Hasell J, Macdonald B, Beltekian D, Roser M. Coronavirus pandemic (COVID-19). [accessed 2022 Feb 24]. https://ourworldindata.org/coronavirus.
  • Our world in data. COVID-19 vaccine doses administered by manufacturer. [accessed 2022 Feb 24]. https://ourworldindata.org/grapher/covid-vaccine-doses-by-manufacturer?country= European+Union.
  • Freeman D, Waite F, Rosebrock L, Petit A, Causier C, East A, Jenner L, Teale AL, Carr L, Mulhall S, et al. Coronavirus conspiracy beliefs, mistrust, and compliance with government guidelines in England. Psychol Med. 2022;52(2):251–263. doi:10.1017/S0033291720001890.
  • Romer D, Jamieson KH. Conspiracy theories as barriers to controlling the spread of COVID-19 in the U.S. Soc Sci Med. 2020;263:113356. doi:10.1016/j.socscimed.2020.113356.
  • Ministry of Health, Labor and Welfare. COVID-19 vaccine Navi, the vaccination. Japan. [accessed 2022 Feb 24]. https://v-sys.mhlw.go.jp/en/about/.
  • Berkman LF, Kawachi I, Maria Glymour M. Social epidemiology. 2nd ed Kindle version. New York (NY): Oxford University Press; 2014. p. 290–319.
  • Kawachi I, Subramanian SV, Kim D. Social capital and health. New York (NY): Springer; 2008. p. 1–26.
  • Rönnerstrand B. Contextual generalized trust and immunization against the 2009 A(H1N1) pandemic in the American states: a multilevel approach. SSM Popul Health. 2016;2:632–639. doi:10.1016/j.ssmph.2016.08.004.
  • Rönnerstrand B. Social capital and immunization against the 2009 A(H1N1) pandemic in the American States. Public Health. 2014;128(8):709–715. doi:10.1016/j.puhe.2014.05.015.
  • Nawa N, Fujiwara T. Association between social capital and second dose of measles vaccination in Japan: results from the A-CHILD study. Vaccine. 2019;37(6):877–881. doi:10.1016/j.vaccine.2018.12.037.
  • Iwai-Saito K, Shobugawa Y, Kondo K. Social capital and pneumococcal vaccination (PPSV23) in community-dwelling older Japanese: a JAGES multilevel cross-sectional study. BMJ Open. 2021;11(6):e043723. doi:10.1136/bmjopen-2020-043723.
  • Chuang YC, Huang YL, Tseng KC, Yen CH, Yang LH. Social capital and health-protective behavior intentions in an influenza pandemic. Plos One. 2015;10(4):e0122970. doi:10.1371/journal.pone.0122970.
  • Rönnerstrand B. Social capital and immunisation against the 2009 A(H1N1) pandemic in Sweden. Scand J Public Health. 2013;41(8):853–859. doi:10.1177/1403494813494975.
  • Jung M, Lin L, Viswanath K. Associations between health communication behaviors, neighborhood social capital, vaccine knowledge, and parents’ H1N1 vaccination of their children. Vaccine. 2013;31(42):4860–4866. doi:10.1016/j.vaccine.2013.07.068.
  • Vikram K, Vanneman R, Desai S. Linkages between maternal education and childhood immunization in India. Soc Sci Med. 2012;75(2):331–339. doi:10.1016/j.socscimed.2012.02.043.
  • Chiatti C, Barbadoro P, Lamura G, Pennacchietti L, Di Stanislao F, D’-Errico MM, Prospero E. Influenza vaccine uptake among community-dwelling Italian elderly: results from a large cross-sectional study. BMC Public Health. 2011;11(1):207. doi:10.1186/1471-2458-11-207.
  • Ferwana I, Varshney LR. Social capital dimensions are differentially associated with COVID-19 vaccinations, masks, and physical distancing. Plos One. 2021;16(12):e0260818. doi:10.1371/journal.pone.0260818.
  • Qiao S, Li Z, Zhang J, Sun X, Garrett C, Li X. Social capital, urbanization level, and COVID-19 vaccination uptake in the United States: a national level analysis. Vaccines. 2022;10(4):625. doi:10.3390/vaccines10040625.
  • Machida M, Nakamura I, Kojima T, Saito R, Nakaya T, Hanibuchi T, Takamiya T, Odagiri Y, Fukushima N, Kikuchi H, et al. Acceptance of a COVID-19 vaccine in Japan during the COVID-19 pandemic. Vaccines. 2021;9(3):210. doi:10.3390/vaccines9030210.
  • Nichol KL, Korn JE, Baum P. Estimation of outpatient risk characteristics and influenza vaccination status: validation of a self-administered questionnaire. Am J Prev Med. 1991;7(4):199–203. doi:10.1016/S0749-3797(18)30913-9.
  • Zimmerman RK, Raymund M, Janosky JE, Nowalk MP, Fine MJ. Sensitivity and specificity of patient self-report of influenza and pneumococcal polysaccharide vaccinations among elderly outpatients in diverse patient care strata. Vaccine. 2003;21(13–14):1486–1491. doi:10.1016/s0264-410x(02)00700-4.
  • Our world in data. Coronavirus (COVID-19) vaccinations. [accessed 2022 Feb 24]. https://ourworldindata.org/covid-vaccinations.
  • Our world in data. COVID-19 vaccine boosters administered. [accessed 2022 Feb 24]. https://ourworldindata.org/grapher/cumulative-covid-vaccine-booster-doses.
  • Saito M, Kondo N, Aida J, Kawachi I, Koyama S, Ojima T, Kondo K. Development of an instrument for community-level health related social capital among Japanese older people: the JAGES project. J Epidemiol. 2017;27(5):221–227. doi:10.1016/j.je.2016.06.005.
  • Fine P, Eames K, Heymann DL. ‘Herd immunity’: a rough guide. Clin Infect Dis. 2011;52(7):911–916. doi:10.1093/cid/cir007.
  • Betsch C, Schmid P, Heinemeier D, Korn L, Holtmann C, Böhm R, Angelillo IF. Beyond confidence: development of a measure assessing the 5C psychological antecedents of vaccination. Plos One. 2018;13(12):e0208601. doi:10.1371/journal.pone.0208601.
  • Story WT. Social capital and the utilization of maternal and child health services in India: a multilevel analysis. Health Place. 2014;28:73–84. doi:10.1016/j.healthplace.2014.03.011.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.